TGA / PMDA / NMPA · Asia-Pacific
immunomodulatory — TGA / PMDA / NMPA regulatory status
immunomodulatory regulatory status in the Asia-Pacific is tracked from public TGA / PMDA / NMPA records and cross-linked clinical and patent datasets on NovaPharmaNews. Current status: NMPA clinical trials.
Status snapshot
- Status
- NMPA clinical trials
- Structured fields
- 4
Regional decision snapshot — NMPA: clinical trials.
Linked evidence on this spoke: 4 published clinical programs and 12 related patent records. Use the tables below for NCT identifiers, phases, and exclusivity dates; verify against primary sources before BD or medical decisions.
Regulatory timeline
| Regulator | Region | Status | Date | Source |
|---|---|---|---|---|
| NMPA | China | clinical trials | — | Evidence |
Linked clinical programs
| Program | Phase | Sponsor | NCT |
|---|---|---|---|
| Adjuvant Immunomodulatory (IM) Therapy | Phase 3 | Ultragenyx UK | NCT04360265 |
| BB2121-MM-003 | Phase 3 | Celgene | 2023-509848-10-00 |
| KT-US-679-0788 | Phase 3 | Anaxis Pharma | 2024-511188-26-00 |
| Immunomodulatory DC vaccines to target prostate cancer | Phase 2 | Shenzhen Second People's | NCT07068555 |
Related patents
| Number | Title | Jurisdiction |
|---|---|---|
| 11993641 | Methods for modulating an immune response | US |
| 11958893 | Methods for modulating an immune response | US |
| 11767355 | Methods for modulating an immune response | US |
| 11702461 | T-cell modulatory multimeric polypeptides comprising reduced-affinity immunomodulatory polypeptides | US |
| 11696896 | Immunomodulatory nanoparticle treatment of brain injury | US |
| 11479595 | Methods for modulating an immune response | US |
| 11104712 | Methods for modulating an immune response | US |
| 2021163596 | IMMUNOMODULATORY IL-2 AGENTS IN COMBINATION WITH IMMUNE CHECKPOINT INHIBITORS | US |
| 10927161 | Methods for modulating an immune response | US |
| 10001483 | Methods for the treatment of Kaposi's sarcoma or KSHV-induced lymphoma using immunomodulatory compounds, and uses of biomarkers | US |
| 9717827 | Immunomodulatory materials for implantable medical devices | US |
| 8557859 | Immunomodulatory compositions | US |
Related hubs
FAQ
What is the TGA / PMDA / NMPA approval status of immunomodulatory?
immunomodulatory currently shows NMPA clinical trials in our Asia-Pacific regulatory index. Confirm on the official TGA / PMDA / NMPA label or EPAR before clinical or commercial use.
Where does NovaPharmaNews get immunomodulatory regulatory data?
Status fields are joined from public sources (openFDA / EMA / regional agencies), ClinicalTrials.gov-linked programs, and patent registries. See /about/data-sources for attribution.
How many clinical programs are linked to immunomodulatory?
This spoke lists 4 published programs associated with immunomodulatory in our pipeline index.